Psilocybin for Addiction: Matthew Johnson on Smoking Cessation and Beyond
About This Video
Matthew Johnson presents the findings from the Johns Hopkins smoking cessation trial and discusses the broader implications for addiction medicine. The 80% smoking abstinence rate at 6 months — compared to 35% for the best available conventional treatments — is the headline finding, but Johnson spends considerable time explaining why and how psilocybin works against addiction in ways that pharmacological approaches generally don't. The key insight: addiction is maintained by rigid psychological patterns, habitual self-narratives, and the compulsive pull of the habit loop. Psilocybin disrupts all three simultaneously via DMN suppression, neuroplasticity promotion, and the motivational transformation associated with the mystical experience. Johnson is careful to note that the therapeutic context is not incidental — preparation and integration work appear to be essential components, not optional supplements.
Key Takeaways
- 80% smoking abstinence at 6 months — more than double the best conventional treatment outcomes.
- The mechanism involves simultaneously disrupting habit loops, self-narratives, and the compulsive drive through DMN suppression.
- The strength of the mystical experience during the session is the single strongest predictor of long-term abstinence.
- Preparation (several sessions before psilocybin) and integration (sessions after) are essential to outcomes, not optional.
- Johnson discusses extending this work to alcohol use disorder and opioid addiction, where early data is also promising.
Dive Deeper
Continue exploring this topic on LearnShrooms: